Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
about
Allogeneic stem cell transplantation with matched sibling donor versus autologous stem cell transplantation for newly diagnosed Multiple MyelomaThe effects of allogeneic stem cell transplantation with matched sibling donor versus autologous stem cell transplantation for newly diagnosed multiple myelomaInterpretation of cytogenetic results in multiple myeloma for clinical practiceInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationThe role of SLAMF7 in multiple myeloma: impact on therapy.Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.TPL2 kinase regulates the inflammatory milieu of the myeloma nicheBortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survivalImpact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myelomaSingle-molecule analysis reveals widespread structural variation in multiple myeloma.Curative one-shot systemic virotherapy in murine myeloma.Detection of t(14;16)(q32;q22) and Monosomy 13 by FISH Analysis in a Patient with Multiple Myeloma Associated with Sjögren's Syndrome: The First Case Report from India.Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markersFOXM1 is a therapeutic target for high-risk multiple myeloma.Outcomes of salvage autologous versus allogeneic hematopoietic cell transplantation for relapsed multiple myeloma after initial autologous hematopoietic cell transplantation.Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma.Wnt and Wnt inhibitors in bone metastasis.Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myelomaResponsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levelsRelationship between initial clinical presentation and the molecular cytogenetic classification of myeloma.Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.Bortezomib for the treatment of previously untreated multiple myeloma.Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.Association of response endpoints with survival outcomes in multiple myeloma.Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.Optimal management of elderly patients with myeloma.Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myelomaA phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.The potential diagnostic power of extracellular vesicle analysis for multiple myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Current Role of Genetics in Hematologic Malignancies.Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.Expression of cancer-testis antigen in multiple myeloma.Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.New rising infection: human herpesvirus 6 is frequent in myeloma patients undergoing autologous stem cell transplantation after induction therapy with bortezomib.Apoptotic machinery diversity in multiple myeloma molecular subtypes.Is there an optimal timing of autologous stem-cell transplantation for multiple myeloma in the era of novel agents?Multiple osteolytic lesions.Distinct and shared three-dimensional chromosome organization patterns in lymphocytes, monoclonal gammopathy of undetermined significance and multiple myeloma.
P2860
Q24198198-AD983ECD-1E70-4913-9853-39F743820A01Q26471825-2E781434-3BC4-47B7-AF50-68FE99670DC6Q26777803-E50B377C-54B5-4969-89FB-51D9DA4B96B6Q27002668-96D1042D-EBC4-4BE8-A3E0-E032E7295393Q30249167-5A48EC02-2434-4064-917F-EE2D761EEE5AQ33404749-BAD34601-9153-4438-8FE0-C2996440B5D6Q33714724-AAF8BC00-4806-437B-816F-D6EBA903EA55Q33831838-3B5D1942-EBE6-452D-9BB1-938A89C34D9DQ34115051-D500E7E7-1A03-4A3B-A7B7-D2782C9576E5Q35247381-B65AFBB1-600F-4640-8EE7-48764D44FE5BQ35796097-6B4E48B2-6651-420A-B547-A7A0FF4DBD49Q36139716-E8B82137-937C-4E3C-9AFC-F2EC12772657Q36582629-89E66FC1-BB47-4540-BA74-27B6D16DF2F5Q36665156-F0547D3B-1A46-4791-9C02-9FF5E0388D29Q36783627-3C9F5C80-9870-450F-BFBF-F3BF839AFDABQ36834629-22C3F96A-43E1-4AE8-8728-AEC0AB8305C3Q36973054-7B01D719-7882-47DE-856D-CDC95709C261Q37056355-426299FA-8F92-4B42-BBC6-AF9504E75AD0Q37146231-240258D0-512B-43C6-8035-C7A937848694Q37325843-985718ED-41C5-4C4B-85DE-A5F73224C406Q37584754-32F156BA-E717-4877-94D0-105528A90A1EQ38020248-AB52779E-A86B-4FF5-AF4E-7D2472C87123Q38096055-4623DBFE-66AA-48CF-A926-5DA88AD40426Q38100588-022FF299-8AD1-4535-9074-413ADF2C5B96Q38122624-B4244730-F231-4AD6-B72C-A90BED1CBC67Q38161731-64D834C2-259B-435D-B757-2AC960DBAF36Q38168925-118F8D9A-D153-4233-8A3E-574134735807Q38219408-C94DA0BC-2F0E-4DFB-B5A0-2CC8268CF752Q38394118-F17B5334-C288-40F1-AEBE-1C8F98A83F74Q38670495-2761CF85-3445-44B0-B80A-49509E2B30C4Q38672091-50FD6680-B923-471D-9878-117CFEF51312Q38726143-0D9F6E3E-B8D9-41AA-86DD-ADE179426E2AQ38810089-7FD8F8D1-9517-4502-A95A-DF451643B1CFQ39006726-1908D1BC-DD06-4A1C-949B-40D4A06EFAF7Q39379927-0F0D95CC-77FB-4E0F-9D9C-53E9F8458954Q40264216-44A67304-EAB1-4BF1-A885-C1ED4E58FF9DQ41807395-31E7222E-B20A-454B-8D27-0C2494E22791Q41846498-68B6109A-F188-41E7-B195-893866669AEDQ41899822-6F8B4C9D-EF04-40BA-922D-96446CA81943Q42082177-BB4184F2-D165-433E-9A7D-B8755FE8D725
P2860
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
@ast
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
@en
type
label
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
@ast
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
@en
prefLabel
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
@ast
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
@en
P2860
P356
P1476
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.
@en
P2093
S Vincent Rajkumar
P2860
P356
10.1002/AJH.22237
P577
2012-01-01T00:00:00Z